Chugai Pharmaceutical Co.
The Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社, Chūgai Seiyaku kabushiki gaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014.[1] The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.
Native name | 中外製薬株式会社 |
---|---|
Romanized name | Chūgai Seiyaku kabushiki gaisha |
Public KK | |
Traded as |
|
ISIN | JP3519400000 |
Industry | Pharmaceutical Industry, Business import, production and development of drugs for medical sales |
Founded | March 8, 1943 |
Headquarters | Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo On the registration Headquarter: Tokyo Kita (Tokyo) |
Key people | Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO |
Revenue | 72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated (December 2007) |
Parent | Hoffmann-La Roche (61.62%) |
Website | www |
History
- 1961 – Developed patents for synthesis of vitamin A
- 1995 – Released acute promyelocytic sphere of leukemia drug treatment Vesanoid.
- 1996 – Released anti-viral chemotherapeutic agent Hivid (HIV reverse transcriptase inhibitor)
- 1997 – Released HIV protease inhibitor Invirase
- 1999 – Released immunosuppressive agent Cellcept
- 2000 – Releasd antiemetic drug Kytril, developed to combat the side effects of chemotherapy
- 2001 – Produced anti-influenza virus Tamiflu (Roche)
- 2011 – Produced Actemra, a human IL-6 receptor monoclonal antibody for rheumatoid arthritis
- 2015 – In March the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of US$205 million.[2]
- 2020 – FDA approved satralizumab (Enspryng) for treatment of the orphan disease neuromyelitis optica.[3]
gollark: APPARENTLY RDanny tags CANNOT be used for BISMUTHIC purposes.
gollark: Tags can trigger ABR commands for maximum funlolz.
gollark: ?tag not found
gollark: ?tag php
gollark: ?tag edit php https://media.discordapp.net/attachments/348702212110680064/801760566804742164/php.png
See also
- Biotech and pharmaceutical companies in the New York metropolitan area
References
- Cortez, Michelle Fay; Matsuyama, Kanoko (25 August 2014). "Roche Said to Have Decided Against Bid for Rest of Chugai". Bloomberg.
- Staff (2 March 2015). "Chugai to Co-Develop Athersys' Cell Therapy in Japan in Up-to-$205M Partnership". Genetic Engineering & Biotechnology News (Paper, Vol 35, i 7, p. 12). Retrieved 11 June 2016.
- "FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord". U.S. Food and Drug Administration. 17 August 2020. Retrieved 18 August 2020.
External links
- Chugai Pharmaceutical Co., Ltd. English version of company homepage
- The transfer of operations of the Company
Wikimedia Commons has media related to Chugai Pharmaceutical. |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.